[go: up one dir, main page]

DE69232636D1 - CNP-Analoge Peptide und ihre Verwendung - Google Patents

CNP-Analoge Peptide und ihre Verwendung

Info

Publication number
DE69232636D1
DE69232636D1 DE69232636T DE69232636T DE69232636D1 DE 69232636 D1 DE69232636 D1 DE 69232636D1 DE 69232636 T DE69232636 T DE 69232636T DE 69232636 T DE69232636 T DE 69232636T DE 69232636 D1 DE69232636 D1 DE 69232636D1
Authority
DE
Germany
Prior art keywords
ser
arg
gly
phe
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232636T
Other languages
English (en)
Other versions
DE69232636T2 (de
Inventor
Shoji Tanaka
Yoshiharu Minamitake
Yasuo Kitajima
Mayumi Furuya
Hisayuki Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATSUO, HISAYUKI, KOBE, HYOGO, JP
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of DE69232636D1 publication Critical patent/DE69232636D1/de
Application granted granted Critical
Publication of DE69232636T2 publication Critical patent/DE69232636T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69232636T 1991-01-31 1992-01-31 CNP-Analoge Peptide und ihre Verwendung Expired - Lifetime DE69232636T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1132191 1991-01-31
JP3254066A JP2809533B2 (ja) 1991-01-31 1991-06-28 Ｃｎｐ類似体ペプチド

Publications (2)

Publication Number Publication Date
DE69232636D1 true DE69232636D1 (de) 2002-07-18
DE69232636T2 DE69232636T2 (de) 2002-12-05

Family

ID=26346733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232636T Expired - Lifetime DE69232636T2 (de) 1991-01-31 1992-01-31 CNP-Analoge Peptide und ihre Verwendung

Country Status (6)

Country Link
US (1) US5434133A (de)
EP (1) EP0497368B1 (de)
JP (1) JP2809533B2 (de)
AT (1) ATE219103T1 (de)
DE (1) DE69232636T2 (de)
ES (1) ES2178634T3 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6360394A (en) * 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
KR100691545B1 (ko) * 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US9006388B2 (en) * 2003-03-26 2015-04-14 Sudhir Paul Covalent attachment of ligands to nucleophilic proteins guided by non-covalent
EP1638443B1 (de) * 2003-06-20 2010-10-20 Mayo Foundation For Medical Education And Research Isoformen von gehirn-natriuretischem peptid
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
KR101207155B1 (ko) * 2004-03-31 2012-12-04 카즈와 나카오 관절염증 치료제 또는 예방제
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
DK2001518T3 (da) 2006-03-30 2013-10-07 Palatin Technologies Inc Cykliske natriuretiske peptidfremstillinger
CA2647146A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
JP5702930B2 (ja) * 2006-08-08 2015-04-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 利尿ポリペプチドおよびナトリウム利尿ポリペプチド
ES2472791T3 (es) 2007-07-20 2014-07-03 Mayo Foundation For Medical Education And Research Polip�ptidos natriur�ticos
WO2009046873A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Combined use of vasonatrin and gastrin-i as a therapeutic agent
WO2009036448A2 (en) * 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
CL2008003476A1 (es) * 2007-11-21 2009-08-14 Biomarin Pharm Inc Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
KR102225470B1 (ko) 2009-05-20 2021-03-10 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
RU2572694C2 (ru) 2009-07-23 2016-01-20 ИГИСУ Ко., Лтд. Композиция кожного препарата для наружного применения
CN102596216B (zh) 2009-08-27 2016-04-20 远藤京子 鼻炎治疗剂
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP3269382A1 (de) 2011-01-21 2018-01-17 Igisu Co., Ltd. Therapeutischer wirkstoff gegen haarausfall
CN103402542B (zh) * 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104059154B (zh) * 2014-05-06 2017-09-29 中国人民解放军第四军医大学 一种新的具有抗心力衰竭作用的钠尿肽嵌合体cnaac
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
PT3328416T (pt) * 2015-07-30 2024-04-10 Biomarin Pharm Inc Utilização de variantes do péptido natriurético de tipo c para tratar as displasias esqueléticas
CA2994091A1 (en) * 2015-07-31 2017-02-09 Igisu Co., Ltd. A cnp cyclic peptide and a medicament, external preparation and cosmetic comprising the cyclic peptide
CA2993358A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
DK3386531T3 (da) 2015-12-08 2022-01-03 Biomarin Pharm Inc Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289B1 (de) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa zur behandlung von tracheobronchomalazie
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
MX2023009463A (es) 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.
WO2024086680A2 (en) 2022-10-21 2024-04-25 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
TW202419463A (zh) 2022-11-02 2024-05-16 丹麥商諾佛 儂迪克股份有限公司 Cnp化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
EP0232078A3 (de) * 1986-01-31 1990-03-14 Merck & Co. Inc. Peptide mit ANF-Wirkung
EP0292256A3 (de) * 1987-05-19 1990-10-03 Merck & Co. Inc. Peptide mit ANF-Wirksamkeit
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
DK380288D0 (da) * 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
EP0478797B1 (de) * 1990-04-20 1995-04-12 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide
JP2801079B2 (ja) * 1990-11-14 1998-09-21 サントリー株式会社 Ａｎｐ関連新規ペプチド

Also Published As

Publication number Publication date
EP0497368A1 (de) 1992-08-05
ATE219103T1 (de) 2002-06-15
JP2809533B2 (ja) 1998-10-08
DE69232636T2 (de) 2002-12-05
EP0497368B1 (de) 2002-06-12
JPH069688A (ja) 1994-01-18
US5434133A (en) 1995-07-18
ES2178634T3 (es) 2003-01-01

Similar Documents

Publication Publication Date Title
DE69232636D1 (de) CNP-Analoge Peptide und ihre Verwendung
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE162201T1 (de) Cnp-gen und vorläuferprotein aus schwein
CA2121724A1 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
CO4750841A1 (es) Compuestos ciclicos, inhibidores de la adhesion
UA35636C2 (uk) Поліпептид, який має активність легеневої поверхнево-активної речовини, та фармацевтична композиція для лікування респіраторного дистрес-синдрому у ссавців
WO1998021237A3 (en) Peptide compounds useful for modulating FGF receptor activity
EP0378641A4 (en) Novel antimicrobial peptide, compositions containing same and uses thereof
ATE154387T1 (de) Cdna für ratten c-typ natriuretisches peptid und vorläuferprotein
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DK302388D0 (da) Proteiner
TW224975B (de)
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
EP0292257A3 (de) Peptide mit ANF-Wirksamkeit
EP0310887A3 (en) Vasoconstrictor peptide
EP0330700A4 (de) Menschlicher Prourokinase ähnliches Polypeptid.
GB1294771A (en) Thyrocalcitonin derivative
DE3751398D1 (de) Substrat-Peptide.
EP0687685A4 (de) Physiologisch-aktive peptide
JPS6426598A (en) Calcitonin gene related peptide derivative
KR950011466A (ko) 선형 결합 억제제
DE453719T1 (de) Bakteriozin-peptid.
AU633128B2 (en) Anticoagulant peptides
ATE152733T1 (de) Bradykinin-antagonisten zur behandlung von akuter pankreatitis

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI SUNTORY PHARMA CO., LTD., TOKIO/TOKYO, JP

Owner name: MATSUO, HISAYUKI, KOBE, HYOGO, JP

8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI ASUBIO PHARMA CO., LTD., TOKIO/TOKYO, JP

Owner name: MATSUO, HISAYUKI, KOBE, HYOGO, JP

8327 Change in the person/name/address of the patent owner

Owner name: ASUBIO PHARMA CO., LTD., TOKYO, JP

Owner name: MATSUO, HISAYUKI, KOBE, HYOGO, JP